- Home
- PROK vs MCI Comparison
PROK vs MCI Comparison
Compare PROK & MCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PROK
- MCI
- Stock Information
- Founded
- PROK 2015
- MCI 1971
- Country
- PROK United States
- MCI United States
- Employees
- PROK N/A
- MCI N/A
- Industry
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- MCI Trusts Except Educational Religious and Charitable
- Sector
- PROK Health Care
- MCI Finance
- Exchange
- PROK Nasdaq
- MCI Nasdaq
- Market Cap
- PROK 384.2M
- MCI 419.4M
- IPO Year
- PROK N/A
- MCI N/A
- Fundamental
- Price
- PROK $2.17
- MCI $21.27
- Analyst Decision
- PROK Buy
- MCI
- Analyst Count
- PROK 5
- MCI 0
- Target Price
- PROK $6.25
- MCI N/A
- AVG Volume (30 Days)
- PROK 1.7M
- MCI 40.4K
- Earning Date
- PROK 08-12-2025
- MCI 01-01-0001
- Dividend Yield
- PROK N/A
- MCI 8.46%
- EPS Growth
- PROK N/A
- MCI N/A
- EPS
- PROK N/A
- MCI 1.82
- Revenue
- PROK $527,000.00
- MCI N/A
- Revenue This Year
- PROK $265.05
- MCI N/A
- Revenue Next Year
- PROK N/A
- MCI N/A
- P/E Ratio
- PROK N/A
- MCI $9.88
- Revenue Growth
- PROK N/A
- MCI N/A
- 52 Week Low
- PROK $0.46
- MCI $12.96
- 52 Week High
- PROK $7.13
- MCI $19.24
- Technical
- Relative Strength Index (RSI)
- PROK 41.52
- MCI 52.68
- Support Level
- PROK $2.23
- MCI $21.16
- Resistance Level
- PROK $2.44
- MCI $21.90
- Average True Range (ATR)
- PROK 0.15
- MCI 0.41
- MACD
- PROK -0.02
- MCI 0.03
- Stochastic Oscillator
- PROK 6.07
- MCI 60.00
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
About MCI Barings Corporate Investors
Barings Corporate Investors is a closed-end management investment company. Its investment objective is to maintain a portfolio of securities providing a current yield and an opportunity for capital gains. The Trust's principal investments are privately placed, below-investment grade, long-term debt obligations, including bank loans and mezzanine debt instruments. The Trust typically purchases these investments, which are not publicly tradable, directly from their issuers in private placement transactions, and the investments are typically made to small or middle market companies.